CRDL News and Press, Cardiol Therapeutics Inc. From 11/13/25

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...

Cardiol Therapeutics Inc. (CRDL) is expected to report $-0.09 for Q3 2025

The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis. Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular ...

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and th...

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and th...

Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces t...

Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces t...

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focu...

2025-04-20 18:48:53 ET Cardiol Therapeutics Inc. (CRDL) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.99%. The average open to low on the day of earnings was -4.35%. The average open...